[PRNewswire] Merck to Showcase New Data at ACTRIMS-ECTRIMS ... (1/2)
MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis
- Not intended for UK and US based media
- Company to present 54 abstracts across its MS portfolio - MAVENCLAD(R) (cladribine tablets), Rebif(R) (interferon beta-1a) and investigational evobrutinib
- New long-term data and real-world evidence further characterise efficacy and safety of MAVENCLAD(R)
- New MAVENCLAD(R) and Rebif(R) safety data to be shared demonstrating no increased risk of respiratory viral infections
(DARMSTADT, Germany, Sept. 3, 2020 PRNewswire=연합뉴스) Merck, a leading science and technology company, today announced it will present data on its approved and investigational multiple sclerosis (MS) treatments at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting. Merck will present 54 abstracts at the meeting, taking place virtually from 11-13 September 2020, including new efficacy and real-world safety data on MAVENCLAD(R) (cladribine tablets) and new safety data for Rebif(R) (interferon beta-1a).
In addition, data will be presented demonstrating investigational evobrutinib is the first and only Bruton's Tyrosine Kinase inhibitor (BTKi) to demonstrate high and sustained efficacy through 108 weeks in clinical studies. Preclinical data will also be presented providing insights into evobrutinib`s potential impact on progression in MS.
"The broad range of research revealed through these data demonstrate our strategic approach to advancing the MS treatment landscape through new medicines and patient-focused research initiatives," said Luciano Rossetti, Head of Global Research & Development for the biopharma business of Merck. "Much of our data provide insights on how MAVENCLAD(R) and Rebif(R) affect the risk of respiratory viral infections and COVID-19 outcomes in MS patients. These insights will help support clinicians as they make treatment decisions for their patients living with MS."
Key MAVENCLAD (R) (cladribine tablets) data include:
- Early onset of action: Efficacy results from the Phase IV MAGNIFY-MS study, demonstrating an early onset of action from end of month one through a reduction in mean combined unique active (CUA) lesion count in the first six months of MAVENCLAD(R) treatment for highly active relapsing multiple sclerosis (RMS)
- Sustained efficacy:
-- New data evaluating cumulative relapse incidence over five years in patients enrolled in the CLARITY and CLARITY Extension trials, showing the sustained efficacy of MAVENCLAD(R)
-- Late-breaking interim data from the CLASSIC-MS study on the long-term efficacy and real-world treatment patterns for patients receiving MAVENCLAD(R), with eight to 14 years of follow up, will be available as part of the late-breaker sessions from 25 September 2020
- Disability improvement: Results from a post hoc analysis from the CLARITY Extension, showing patients receiving early treatment with MAVENCLAD(R) had a greater prevalence of disability improvement over five years, as measured by the Expanded Disability Status Scale (EDSS)
- COVID-19 patient cases: Results from the MAGNIFY and CLARIFY studies, demonstrating clinical outcomes in patients with COVID-19 infection during these Phase IV studies of MAVENCLAD(R) for the treatment of MS will be available as part of the late-breaker sessions from 25 September 2020
- Updated post-approval safety data of MAVENCLAD(R) in the treatment of MS showing that respiratory viral infections were typically non-serious, and consistent with that from the clinical development program
Key Rebif (R) (interferon beta-1a) data include:
- Post-approval results on the safety of Rebif(R) in the treatment of MS, showing no new safety signals, including no increased risk for respiratory viral infections
Key evobrutinib data include:
- Results of the Phase II open-label extension (OLE) in patients treated with evobrutinib 75 mg BID (twice a day), showing the efficacy at Week 48 was maintained at 108 weeks (ARR, 0.11) and the maximum efficacy observed with BID dosing correlated with optimal BTK occupancy achieved with BID dosing
- Safety results from the ≥60 week Phase II OLE showing no new safety signals identified, consistent with data seen in more than 1,200 patients who have received evobrutinib to date, across MS and other conditions
- Preclinical data demonstrating evobrutinib's potential to reduce CNS compartmentalized inflammation thought to drive the progression of disability seen in MS
Additional Merck activities at MSVirtual2020:
- Live presentation "Exploring the role of real-world data in multiple sclerosis" chaired by Prof. Gavin Giovannoni, Chair of Neurology, Barts and The London School of Medicine and Dentistry (12 September 2020, 14:30-15:30 EDT / 20:30-21:30 CEST; recording available after the event)
- Two product theatres on demand throughout the congress starting from 11 September 2020, 11:45 EDT / 17:45 CEST
-- "Multiple sclerosis patient management: update from the UK" by Dr. Wallace Brownlee, MS Specialist Neurologist, National Hospital for Neurology and Neurosurgery, and MS researcher at Queen Square MS Centre, University College London Institute of Neurology
-- "Real-world multiple sclerosis management: what can we learn from MSBase?" by Dr. Suzanne Hodgkinson, Associate Professor, University of New South Wales, and a senior consultant neurologist at Liverpool Hospital, New South Wales, Australia
Today, Merck has launched a newsroom for journalists interested in the company`s latest developments and news - merckneurology.com/newsroom - where, among other information, background information on Merck MS treatments, and video presentations from the below will be available:
- Merck's commitment to MS: Andrew Paterson, Senior Vice President, Head of Global and US Multiple Sclerosis Franchise, Merck
- An overview of MAVENCLAD(R) MAGNIFY data: Prof. Nicola De Stefano, PhD, Professor of Neurology, Department of Medicine, Surgery & Neuroscience, University of Siena, Italy
- Evobrutinib clinical trial update: Robert Henderson, Vice President, Global Program Leadership, Neurology & Immunology, Merck
Following the conclusion of MSVirtual2020, Merck will be hosting "Mastering the Neuroscience of Unconscious Bias," the inaugural virtual event for Merck's I'M IN initiative, a diversity, equity and inclusion effort started in February 2019. I'M IN is an initiative started by Merck`s Neurology & Immunology franchise, which aims to explore solutions together with healthcare providers to improve equity within the healthcare ecosystem.
Below is the full list of Merck abstracts accepted for presentation at ACTRIMS-ECTRIMS 2020:
MAVENCLAD(R) (cladribine tablets) Presentations
Title: Reduced Grey Matter Atrophy in Patients With Relapsing Multiple Sclerosis Treated With Cladribine Tablets
Authors: Battaglini M, Sormani M P, Luchetti L, Gentile G, Cortese R, Alexandri N, De Stefano N
Presentation ID: P0231
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Marco Battaglini
Title: Reduction in CUA MRI Lesions in the First 6 Months of Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Study
Authors: De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L. Schmierer K, Sellebjerg F, Vermersch P, Wiendl H, Keller B, Roy S
Presentation ID: P0382
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Nicola De Stefano
Title: Durable Efficacy of Cladribine Tablets: Cumulative Relapse Incidence Over 5 years in CLARITY and CLARITY Extension
Authors: Giovannoni G, Rammohan K, Leist T, Coyle P K, Keller B, Jack D, Alexandri N
Presentation ID: P0202
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Gavin Giovannoni
Title: Disability Improvement in Relapsing-remitting Multiple Sclerosis Patients Receiving Cladribine Tablets, Evaluated by Expanded Disability Status Scale
Authors: Sormani M P, Signori A Giovannoni G, Alexandri N
Presentation ID: P0201
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Maria Pia Sormani
Title: Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections
Authors: Giovannoni G, Berger J, Leist T, Jack D, Galazka A, Nolting A, Damian D
Presentation ID: P0415
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Gavin Giovannoni
Title: Clinical Outcomes in Patients With COVID-19 Infection During Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis
Authors: Karan R, Roy S, Alexandri N
Presentation ID: LB1151
Presentation Details:
- Session: Latebreaker ePoster
- Date: 25-26 September 2020
- Time: Available from 9am EDT on 25 September 2020
- Presenter: Radmila Karan
Title: Treatment Satisfaction in Patients With Highly-active Relapsing Multiple Sclerosis Treated With Cladribine Tablets: CLARIFY-MS Study Interim Analysis
Authors: Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B
Presentation ID: P1066
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Bruno Brochet
Title: Initial Findings From a Dynamic Cohort Study of Patients With Multiple Sclerosis: A Proactive Approach for Safety and Comparative Effectiveness
Authors: Sabido, M, Batech M, Foch C, Boutmy E, Verpillat P
Presentation ID: P0470
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Meritxell Sabido
Title: Characteristics of Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets in Five European Countries: Multi-year Chart Review
Authors: Zeng F, Harty G, Wong SL, Maslova E, Schade R, Row B
Presentation ID: P0846
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Feng Zeng
Title: Characterization of Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets in Germany Since Marketing Authorization
Authors: Zeng F, Harty G, Wong SL, Uebler S, Maslova E, Schade R, Row B, Ellenberger D, Stahmann A
Presentation ID: P0847
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Feng Zeng
Title: CLASSIC-MS: Long-term Efficacy and Real-World Treatment Patterns for Patients Receiving Cladribine Tablets - Interim Data with 8-14 Years Follow-up
Authors: Giovannoni G, Leist T, Aydemir A, Verdun Di Cantogno E, on behalf of the CLASSIC-MS Steering Committee
Presentation ID: LB1229
Presentation Details:
- Session: Latebreaker ePoster
- Date: 25-26 September 2020
- Time: Available from 9am EDT on 25 September 2020
- Presenter: Thomas Leist
Title: Age-related Efficacy of Cladribine Tablets in Patients With Relapsing-remitting MS in the CLARITY Extension Study
Authors: Freedman M, Pardo G, De Stefano N, Aldridge J, Hyvert Y, Galazka A, Lemieux C
Presentation ID: P0284
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Mark Freedman
Title: Cladribine Tablets in Patients with RRMS and Active SPMS After Suboptimal Response to Prior DMD (MASTER-2 and CLICK-MS): Initial Baseline Demographics
Authors: Miravelle A, Katz J, Robertson D, Hayward B, Walsh JS, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ
Presentation ID: P0310
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Augusto Miravelle
Title: Treatment-emergent Adverse Events Occurring Early in the Treatment Course of Cladribine Tablets in two Phase 3 Trials in Multiple Sclerosis
Authors: Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson L, Leist TP
Presentation ID: P0411
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Jiwon Oh
Title: Identification and Characterization of Adherence Trajectory Subgroups in Patients With MS Initiating Once- or Twice-daily Oral Disease-modifying Drugs
Authors: Cisternas MG, Rajagopalan D, Leszko M, Andrade K, Phillips AL
Presentation ID: P0967
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Amy Phillips
Title: Real-world Patient-level Costs of Administering Infusion Disease-modifying Drugs: A US Retrospective Claims Database Analysis
Authors: Kozma CM, Roberts NL, Phillips AL
Presentation ID: P1052
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Chris Kozma
Title: Value-added Benefits of a Nurse/Pharmacy-led Service for Patients With Multiple Sclerosis Treated Over 2 Years With Cladribine Tablets in the UK
Authors: Morgan K, Vernon K, Ayer M
Presentation ID: P1069
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Kate Morgan
Title: Demonstrating the Value of a Patient Support Program for Multiple Sclerosis Patients Prescribed Cladribine Tablets in Ireland at the end of Year 1
Authors: Morgan K, Joseph B, Williams V, Kelly M
Presentation ID: P1015
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Kate Morgan
Title: Low Discontinuation Rate and Side-effect Burden After Switching to Cladribine Tablets: Canadian Experience from the adveva(R) Patient Support Program
Authors: Oh J, Giacomini P, Devonshire V, Clift F, Lemieux C, Sabido M, Allignol A, Freedman M
Presentation ID: P0880
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Jiwon Oh
Title: Cladribine Tablets Versus Other Disease-modifying Therapies in Achieving Disability Improvement in Relapsing-remitting Multiple Sclerosis Patients - Network Meta-analysis
Authors: Piasecka-Stryczynska K, Rolka M, Kaczynski Ł, Gorecka M, Wojcik R, Adamek I, Kaczor MP, Rejdak K
Presentation ID: P0040
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: K. Piasecka-Stryczynska
Title: MS Disease-modifying Therapy Sequencing - Natalizumab to Cladribine Tablets - Experience in 46 Patients
Authors: Ziemssen T, Penner IK, Wagner T, Huebschen M, Mueller B, Buescher T, Richter J, Posevitz-Fejfar A
Presentation ID: 566
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Tjalf Ziemssen
Title: Switching disease modifying treatment in relapsing multiple sclerosis: Delphi consensus of the Demyelinating Group of the Spanish Society of Neurology
Authors: Saiz A, Aguera E, Moral E, Brieva L, Rodriguez-Antiguedad A, Casanova-Estruch B, Jordi R, Meca-Lallana V, Garcia-Merino JA, Costa-Frossard L, Arnal-Garice C, Landete L, Meca-Lallana J, Blanco Y, Matias-Guiu J, Ares A, Martinez-Gines ML, Ara JR, Llaneza M, Castillo-Trivino T, Romero L, Perez-Sempere A, Gonzalez-Platas M, Mendibe-Bilbao M
Presentation ID: P0401
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Luis Brieva
Title: CLADQoL (CLADribine Tablets - evaluation of Quality of Life) Study: Evaluating QoL 12 Months After Treatment Initiation with Cladribine Tablets
Authors: Penner IK, Pul R, Kallmann BA, Raji A, Richter J, Wagner T, Mueller B, Buescher T, Posevitz-Fejfar A
Presentation ID: P0849
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Iris-Katharina Penner
Title: Effects of Cladribine on Proliferation, Survival and Cytokine Release of Human Astrocytes
Authors: Eixarch H, Calvo-Barreiro L, Fissolo N, Boschert U, Comabella M, Montalban X, Espejo C
Presentation ID: P0330
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Herena Eixarch
Title: Real-world Experience With Cladribine in the MSBase Registry
Authors: Butzkueven H, Spelman T, Verdun di Cantogno E, Fabris J, Zeng F, G Harty
Presentation ID: P0907
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Helmut Butzkueven
Title: 2-Chlorodeoxyadenosine (Cladribine) Preferentially Inhibits the Biological Activity of Microglia Cells
Authors: Aybar F, Marcora S, Eugenia Samman M, Perez MJ, Pasquini JM, Correale J
Presentation ID: P0270
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Jorge Correale
Title: Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (ChariotMS)
Authors: Lieberman D, Mangat H, Allen-Philby K, Baker D, Barkhof F, Chandran S, Chapman C, Chataway J, Ford H, Giovannoni G, Hobart J, Hooper R, Hussain T, Walker N, Macmanus D, Mihaylova B, Pavitt S
Presentation ID: P0196
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: David Lieberman
Title: Predicting Long-term Sustained Disability Progression in Multiple Sclerosis: Application in the CLARITY Trial
Authors: Sharmin S, Bovis F, Sormani MP, Butzkueven H, Kalincik T and the MSBase study group
Presentation ID: P0131
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: S Sharmin
Title: A Clinical Data Summary for Cladribine Patients Treated at least 12 Months - A Swedish Nationwide Study of the Long-Term Effectiveness and Safety of Cladribine (IMSE 10)
Authors: Forsberg L, Kagstrom S, Hillert J, Nilsson P, Dahle C, Svenningsson A, Lycke J, Landtblom AM, Burman J, Martin C, Sundstrom P, Gunnarsson M, Piehl F, Olsson T
Presentation ID: P0276
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: L Forsberg
Title: Impact of Cladribine Tablets on Brain Volume Protection in Highly Active MS
Authors: Raji A, Winkler G
Presentation ID: P0586
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: A Raji
Title: Early Real-World Safety, Tolerability, and Efficacy of Cladribine Tablets: A Single Center Experience
Authors: Bain J, Jones A, Overholt S, Guenette M, Selchen D, Jiwon Oh
Presentation ID: P0319
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: J Bain
Title: Switching From Ocrelizumab to Cladribine: Real-world Data
Authors: O'Neill DTD, Sharma M, Gonzales B, Vandenheuvel M, Tse B, Hodgkinson SJ
Presentation ID: P0399
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: D O'Neill
Title: The Effect of Cladribine Upon Naive and Activated CD4+ T Regulatory Cells in MS Patients
Authors: Verma ND, Al-Atiyah R, O'Neill D, Sharma M, Tran CT, Hall BM, Hodgkinson SJ
Presentation ID: P0406
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Suzanne Hodgkinson
Rebif(R) (interferon beta-1a) Presentations
Title: A Systematic Review and Meta-analyses of Pregnancy and Fetal Outcomes in Women with Multiple Sclerosis. IMI2 ConcePTION
Authors: Lopez-Leon S, Geissbuehler Y, Sabido M, Turkson, M, Wahlich C, Morris J
Presentation ID: P0278
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Meritxell Sabido
Title: Post-approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections
Authors: Freedman M S, Guehring H, Murgasova Z, Jack D
Presentation ID: P0370
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Mark Freedman
Title: Effect of Neutralizing Antibodies on Pharmacodynamic Biomarkers of Subcutaneous Interferon β-1a in REFLEX and REFLEXION
Authors: Freedman MS, Holmberg KH, Fluck M, Hyvert H, Stinchi S, D'Urso V, Dangond F
Presentation ID: P0323
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Mark Freedman
Title: Baseline Serum Neurofilament Light Chain Levels Predict Conversion to McDonald 2005 MS Within 2 yrs of a First Clinical Demyelinating Event in REFLEX
Authors: Kuhle J, Leppert D, Comi G, De Stefano N, Kappos L, Freedman MS, Issard D, Roy S
Presentation ID: P0032
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Sanjeev Roy
Title: Effect of age on Effectiveness and Discontinuation of Subcutaneous Interferon beta-1a, and Healthcare Utilization, in Patients With Multiple Sclerosis
Authors: Sabido M, Allignol A Marhardt K, Vermersch P, Boutmy EF
Presentation ID: P0320
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Patrick Vermersch
Title: Comparing Infection-related Outcomes in Patients with Multiple Sclerosis and Matched Controls Using Administrative Claims Data
Authors: Bove R, Kozma C, Phillips AL, Harlow DE, Lobo C
Presentation ID: P0451
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Riley Bove
Title: Assessment of the Effectiveness of a Cognitive Behavioral Program for Fatigue (FACETS +) in 110 French Patients with Relapsing Remitting Multiple Sclerosis (RR MS): A randomized, controlled trial (RCT)
Authors: Hemelin F, Marie Claire G, Olivier H, Marie B, Frederic B
Presentation ID: P1095
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Fanny Hamelin
Title: Impact of Interferon-beta Exposure During Early Pregnancy on Relapse Rate
Authors: Tokic M, Thiel S, Litvin N, Ciplea A, Gold R, Hellwig K
Presentation ID: P1126
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: M Tokic
Evobrutinib Presentations
Title: Clinical Relapse Rates in Relapsing MS Patients Treated with the BTK Inhibitor Evobrutinib: Results of an Open-Label Extension to Phase II Study
Authors: Montalban X, Arnold D L, Weber MS, Staikov I, Piasecka-Stryczynska K, Martin E C, Mandel M, Ona V, Dangond F, Wolinsky JS
Presentation ID: P0197
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Fernando Dengond
Title: Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Relapsing Multiple Sclerosis During an Open-label Extension to a Phase II Study
Authors: Montalban, X Arnold D L, Weber M S, Staikov I, Piasecka-Stryczynska K, Martin E C, Mandel M, Ona V, Zima Y, Dengond F, Tomic D, Wolinsky JS
Presentation ID: P0235
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Fernando Dengond
Title: Effect Of Evobrutinib, a BTK Inhibitor, on Immune Cell and Immunoglobulin Levels in Relapsing MS: An Open-Label Extension to a Phase II Study
Authors: Montalban X, Shaw J, Dangond F, Martin EC, Grenningloh R, Ying Li, Weber MS
Presentation ID: P0070
Presentation Details:
- Session: ePoster
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Jamie Shaw
Title: Evobrutinib, a Highly Selective BTK Inhibitor, Prevents Antigen-activation of B Cells and Ameliorates B Cell-mediated Experimental Autoimmune Encephalomyelitis
Authors: Torke S, Pretzsch R, Hausler D, Grenningloh R, Boschert U, Bruck W, Weber MS
Presentation ID: P0334
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Sebastian Torke
Title: Expression of Bruton's Tyrosine Kinase in B Cell-rich Meningeal Infiltrates in two Models of Progressive MS
Authors: Kebir H, Ceja G, Miller MC, Li C, May MJ, Vite CH, Church ME, Grenningloh R, Boschert U, Alvarez JI
Presentation ID: P0962
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Kebir Hania
Title: T-bet+ B-cell Development in MS: Association with Bruton's Tyrosine Kinase Activity and Targeting by Evobrutinib
Authors: Rijvers L, Melief MJ, van Langelaar J, Wierenga-Wolf AF, Marieke van Ham S, Boschert U, Grenningloh R, Smolders J, van Luijn MM
Presentation ID: P0403
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT 11 September 2020
- Presenter: Liza Rijvers
Title: The Bruton's Tyrosine Kinase Inhibitor Evobrutinib Ameliorates Meningeal Inflammation in Experimental Autoimmune Encephalomyelitis
Authors: Kim S, Boschert U Grenningloh R, Bhargava P
Presentation ID: P0404
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Pavan Bhargava
Title: The Validity and Applicability of the PROMIS SF v2.1 - Physical Function (MS) 15a: A new PROMIS(R) Short Form for Assessing Physical Function in Relapsing and Progressive Multiple Sclerosis Types
Authors: Kamudoni P, Amtmann D, Johns J, Cook K, Salem R, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G, Wundes A, Henke C
Presentation ID: P1062
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Paul Kamudoni
Title: The Interpretation and Clinical Application of the PROMIS(R) SF v1.0 - Fatigue (MS) 8b: A PROMIS Short Form for Assessing Fatigue in Relapsing and Progressive Multiple Sclerosis
Authors: Kamudoni P, Johns J, Cook K, Salem R, Henke C, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G,Wundes A, Amtmann D
Presentation ID: P1061
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Paul Kamudoni
Source: Marck
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
<저작권자(c) 연합뉴스, 무단 전재-재배포 금지>
MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis
- Not intended for UK and US based media
- Company to present 54 abstracts across its MS portfolio - MAVENCLAD(R) (cladribine tablets), Rebif(R) (interferon beta-1a) and investigational evobrutinib
- New long-term data and real-world evidence further characterise efficacy and safety of MAVENCLAD(R)
- New MAVENCLAD(R) and Rebif(R) safety data to be shared demonstrating no increased risk of respiratory viral infections
(DARMSTADT, Germany, Sept. 3, 2020 PRNewswire=연합뉴스) Merck, a leading science and technology company, today announced it will present data on its approved and investigational multiple sclerosis (MS) treatments at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting. Merck will present 54 abstracts at the meeting, taking place virtually from 11-13 September 2020, including new efficacy and real-world safety data on MAVENCLAD(R) (cladribine tablets) and new safety data for Rebif(R) (interferon beta-1a).
In addition, data will be presented demonstrating investigational evobrutinib is the first and only Bruton's Tyrosine Kinase inhibitor (BTKi) to demonstrate high and sustained efficacy through 108 weeks in clinical studies. Preclinical data will also be presented providing insights into evobrutinib`s potential impact on progression in MS.
"The broad range of research revealed through these data demonstrate our strategic approach to advancing the MS treatment landscape through new medicines and patient-focused research initiatives," said Luciano Rossetti, Head of Global Research & Development for the biopharma business of Merck. "Much of our data provide insights on how MAVENCLAD(R) and Rebif(R) affect the risk of respiratory viral infections and COVID-19 outcomes in MS patients. These insights will help support clinicians as they make treatment decisions for their patients living with MS."
Key MAVENCLAD (R) (cladribine tablets) data include:
- Early onset of action: Efficacy results from the Phase IV MAGNIFY-MS study, demonstrating an early onset of action from end of month one through a reduction in mean combined unique active (CUA) lesion count in the first six months of MAVENCLAD(R) treatment for highly active relapsing multiple sclerosis (RMS)
- Sustained efficacy:
-- New data evaluating cumulative relapse incidence over five years in patients enrolled in the CLARITY and CLARITY Extension trials, showing the sustained efficacy of MAVENCLAD(R)
-- Late-breaking interim data from the CLASSIC-MS study on the long-term efficacy and real-world treatment patterns for patients receiving MAVENCLAD(R), with eight to 14 years of follow up, will be available as part of the late-breaker sessions from 25 September 2020
- Disability improvement: Results from a post hoc analysis from the CLARITY Extension, showing patients receiving early treatment with MAVENCLAD(R) had a greater prevalence of disability improvement over five years, as measured by the Expanded Disability Status Scale (EDSS)
- COVID-19 patient cases: Results from the MAGNIFY and CLARIFY studies, demonstrating clinical outcomes in patients with COVID-19 infection during these Phase IV studies of MAVENCLAD(R) for the treatment of MS will be available as part of the late-breaker sessions from 25 September 2020
- Updated post-approval safety data of MAVENCLAD(R) in the treatment of MS showing that respiratory viral infections were typically non-serious, and consistent with that from the clinical development program
Key Rebif (R) (interferon beta-1a) data include:
- Post-approval results on the safety of Rebif(R) in the treatment of MS, showing no new safety signals, including no increased risk for respiratory viral infections
Key evobrutinib data include:
- Results of the Phase II open-label extension (OLE) in patients treated with evobrutinib 75 mg BID (twice a day), showing the efficacy at Week 48 was maintained at 108 weeks (ARR, 0.11) and the maximum efficacy observed with BID dosing correlated with optimal BTK occupancy achieved with BID dosing
- Safety results from the ≥60 week Phase II OLE showing no new safety signals identified, consistent with data seen in more than 1,200 patients who have received evobrutinib to date, across MS and other conditions
- Preclinical data demonstrating evobrutinib's potential to reduce CNS compartmentalized inflammation thought to drive the progression of disability seen in MS
Additional Merck activities at MSVirtual2020:
- Live presentation "Exploring the role of real-world data in multiple sclerosis" chaired by Prof. Gavin Giovannoni, Chair of Neurology, Barts and The London School of Medicine and Dentistry (12 September 2020, 14:30-15:30 EDT / 20:30-21:30 CEST; recording available after the event)
- Two product theatres on demand throughout the congress starting from 11 September 2020, 11:45 EDT / 17:45 CEST
-- "Multiple sclerosis patient management: update from the UK" by Dr. Wallace Brownlee, MS Specialist Neurologist, National Hospital for Neurology and Neurosurgery, and MS researcher at Queen Square MS Centre, University College London Institute of Neurology
-- "Real-world multiple sclerosis management: what can we learn from MSBase?" by Dr. Suzanne Hodgkinson, Associate Professor, University of New South Wales, and a senior consultant neurologist at Liverpool Hospital, New South Wales, Australia
Today, Merck has launched a newsroom for journalists interested in the company`s latest developments and news - merckneurology.com/newsroom - where, among other information, background information on Merck MS treatments, and video presentations from the below will be available:
- Merck's commitment to MS: Andrew Paterson, Senior Vice President, Head of Global and US Multiple Sclerosis Franchise, Merck
- An overview of MAVENCLAD(R) MAGNIFY data: Prof. Nicola De Stefano, PhD, Professor of Neurology, Department of Medicine, Surgery & Neuroscience, University of Siena, Italy
- Evobrutinib clinical trial update: Robert Henderson, Vice President, Global Program Leadership, Neurology & Immunology, Merck
Following the conclusion of MSVirtual2020, Merck will be hosting "Mastering the Neuroscience of Unconscious Bias," the inaugural virtual event for Merck's I'M IN initiative, a diversity, equity and inclusion effort started in February 2019. I'M IN is an initiative started by Merck`s Neurology & Immunology franchise, which aims to explore solutions together with healthcare providers to improve equity within the healthcare ecosystem.
Below is the full list of Merck abstracts accepted for presentation at ACTRIMS-ECTRIMS 2020:
MAVENCLAD(R) (cladribine tablets) Presentations
Title: Reduced Grey Matter Atrophy in Patients With Relapsing Multiple Sclerosis Treated With Cladribine Tablets
Authors: Battaglini M, Sormani M P, Luchetti L, Gentile G, Cortese R, Alexandri N, De Stefano N
Presentation ID: P0231
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Marco Battaglini
Title: Reduction in CUA MRI Lesions in the First 6 Months of Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Study
Authors: De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L. Schmierer K, Sellebjerg F, Vermersch P, Wiendl H, Keller B, Roy S
Presentation ID: P0382
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Nicola De Stefano
Title: Durable Efficacy of Cladribine Tablets: Cumulative Relapse Incidence Over 5 years in CLARITY and CLARITY Extension
Authors: Giovannoni G, Rammohan K, Leist T, Coyle P K, Keller B, Jack D, Alexandri N
Presentation ID: P0202
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Gavin Giovannoni
Title: Disability Improvement in Relapsing-remitting Multiple Sclerosis Patients Receiving Cladribine Tablets, Evaluated by Expanded Disability Status Scale
Authors: Sormani M P, Signori A Giovannoni G, Alexandri N
Presentation ID: P0201
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Maria Pia Sormani
Title: Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections
Authors: Giovannoni G, Berger J, Leist T, Jack D, Galazka A, Nolting A, Damian D
Presentation ID: P0415
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Gavin Giovannoni
Title: Clinical Outcomes in Patients With COVID-19 Infection During Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis
Authors: Karan R, Roy S, Alexandri N
Presentation ID: LB1151
Presentation Details:
- Session: Latebreaker ePoster
- Date: 25-26 September 2020
- Time: Available from 9am EDT on 25 September 2020
- Presenter: Radmila Karan
Title: Treatment Satisfaction in Patients With Highly-active Relapsing Multiple Sclerosis Treated With Cladribine Tablets: CLARIFY-MS Study Interim Analysis
Authors: Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B
Presentation ID: P1066
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Bruno Brochet
Title: Initial Findings From a Dynamic Cohort Study of Patients With Multiple Sclerosis: A Proactive Approach for Safety and Comparative Effectiveness
Authors: Sabido, M, Batech M, Foch C, Boutmy E, Verpillat P
Presentation ID: P0470
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Meritxell Sabido
Title: Characteristics of Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets in Five European Countries: Multi-year Chart Review
Authors: Zeng F, Harty G, Wong SL, Maslova E, Schade R, Row B
Presentation ID: P0846
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Feng Zeng
Title: Characterization of Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets in Germany Since Marketing Authorization
Authors: Zeng F, Harty G, Wong SL, Uebler S, Maslova E, Schade R, Row B, Ellenberger D, Stahmann A
Presentation ID: P0847
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Feng Zeng
Title: CLASSIC-MS: Long-term Efficacy and Real-World Treatment Patterns for Patients Receiving Cladribine Tablets - Interim Data with 8-14 Years Follow-up
Authors: Giovannoni G, Leist T, Aydemir A, Verdun Di Cantogno E, on behalf of the CLASSIC-MS Steering Committee
Presentation ID: LB1229
Presentation Details:
- Session: Latebreaker ePoster
- Date: 25-26 September 2020
- Time: Available from 9am EDT on 25 September 2020
- Presenter: Thomas Leist
Title: Age-related Efficacy of Cladribine Tablets in Patients With Relapsing-remitting MS in the CLARITY Extension Study
Authors: Freedman M, Pardo G, De Stefano N, Aldridge J, Hyvert Y, Galazka A, Lemieux C
Presentation ID: P0284
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Mark Freedman
Title: Cladribine Tablets in Patients with RRMS and Active SPMS After Suboptimal Response to Prior DMD (MASTER-2 and CLICK-MS): Initial Baseline Demographics
Authors: Miravelle A, Katz J, Robertson D, Hayward B, Walsh JS, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ
Presentation ID: P0310
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Augusto Miravelle
Title: Treatment-emergent Adverse Events Occurring Early in the Treatment Course of Cladribine Tablets in two Phase 3 Trials in Multiple Sclerosis
Authors: Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson L, Leist TP
Presentation ID: P0411
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Jiwon Oh
Title: Identification and Characterization of Adherence Trajectory Subgroups in Patients With MS Initiating Once- or Twice-daily Oral Disease-modifying Drugs
Authors: Cisternas MG, Rajagopalan D, Leszko M, Andrade K, Phillips AL
Presentation ID: P0967
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Amy Phillips
Title: Real-world Patient-level Costs of Administering Infusion Disease-modifying Drugs: A US Retrospective Claims Database Analysis
Authors: Kozma CM, Roberts NL, Phillips AL
Presentation ID: P1052
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Chris Kozma
Title: Value-added Benefits of a Nurse/Pharmacy-led Service for Patients With Multiple Sclerosis Treated Over 2 Years With Cladribine Tablets in the UK
Authors: Morgan K, Vernon K, Ayer M
Presentation ID: P1069
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Kate Morgan
Title: Demonstrating the Value of a Patient Support Program for Multiple Sclerosis Patients Prescribed Cladribine Tablets in Ireland at the end of Year 1
Authors: Morgan K, Joseph B, Williams V, Kelly M
Presentation ID: P1015
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Kate Morgan
Title: Low Discontinuation Rate and Side-effect Burden After Switching to Cladribine Tablets: Canadian Experience from the adveva(R) Patient Support Program
Authors: Oh J, Giacomini P, Devonshire V, Clift F, Lemieux C, Sabido M, Allignol A, Freedman M
Presentation ID: P0880
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Jiwon Oh
Title: Cladribine Tablets Versus Other Disease-modifying Therapies in Achieving Disability Improvement in Relapsing-remitting Multiple Sclerosis Patients - Network Meta-analysis
Authors: Piasecka-Stryczynska K, Rolka M, Kaczynski Ł, Gorecka M, Wojcik R, Adamek I, Kaczor MP, Rejdak K
Presentation ID: P0040
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: K. Piasecka-Stryczynska
Title: MS Disease-modifying Therapy Sequencing - Natalizumab to Cladribine Tablets - Experience in 46 Patients
Authors: Ziemssen T, Penner IK, Wagner T, Huebschen M, Mueller B, Buescher T, Richter J, Posevitz-Fejfar A
Presentation ID: 566
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Tjalf Ziemssen
Title: Switching disease modifying treatment in relapsing multiple sclerosis: Delphi consensus of the Demyelinating Group of the Spanish Society of Neurology
Authors: Saiz A, Aguera E, Moral E, Brieva L, Rodriguez-Antiguedad A, Casanova-Estruch B, Jordi R, Meca-Lallana V, Garcia-Merino JA, Costa-Frossard L, Arnal-Garice C, Landete L, Meca-Lallana J, Blanco Y, Matias-Guiu J, Ares A, Martinez-Gines ML, Ara JR, Llaneza M, Castillo-Trivino T, Romero L, Perez-Sempere A, Gonzalez-Platas M, Mendibe-Bilbao M
Presentation ID: P0401
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Luis Brieva
Title: CLADQoL (CLADribine Tablets - evaluation of Quality of Life) Study: Evaluating QoL 12 Months After Treatment Initiation with Cladribine Tablets
Authors: Penner IK, Pul R, Kallmann BA, Raji A, Richter J, Wagner T, Mueller B, Buescher T, Posevitz-Fejfar A
Presentation ID: P0849
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Iris-Katharina Penner
Title: Effects of Cladribine on Proliferation, Survival and Cytokine Release of Human Astrocytes
Authors: Eixarch H, Calvo-Barreiro L, Fissolo N, Boschert U, Comabella M, Montalban X, Espejo C
Presentation ID: P0330
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Herena Eixarch
Title: Real-world Experience With Cladribine in the MSBase Registry
Authors: Butzkueven H, Spelman T, Verdun di Cantogno E, Fabris J, Zeng F, G Harty
Presentation ID: P0907
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Helmut Butzkueven
Title: 2-Chlorodeoxyadenosine (Cladribine) Preferentially Inhibits the Biological Activity of Microglia Cells
Authors: Aybar F, Marcora S, Eugenia Samman M, Perez MJ, Pasquini JM, Correale J
Presentation ID: P0270
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Jorge Correale
Title: Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (ChariotMS)
Authors: Lieberman D, Mangat H, Allen-Philby K, Baker D, Barkhof F, Chandran S, Chapman C, Chataway J, Ford H, Giovannoni G, Hobart J, Hooper R, Hussain T, Walker N, Macmanus D, Mihaylova B, Pavitt S
Presentation ID: P0196
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: David Lieberman
Title: Predicting Long-term Sustained Disability Progression in Multiple Sclerosis: Application in the CLARITY Trial
Authors: Sharmin S, Bovis F, Sormani MP, Butzkueven H, Kalincik T and the MSBase study group
Presentation ID: P0131
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: S Sharmin
Title: A Clinical Data Summary for Cladribine Patients Treated at least 12 Months - A Swedish Nationwide Study of the Long-Term Effectiveness and Safety of Cladribine (IMSE 10)
Authors: Forsberg L, Kagstrom S, Hillert J, Nilsson P, Dahle C, Svenningsson A, Lycke J, Landtblom AM, Burman J, Martin C, Sundstrom P, Gunnarsson M, Piehl F, Olsson T
Presentation ID: P0276
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: L Forsberg
Title: Impact of Cladribine Tablets on Brain Volume Protection in Highly Active MS
Authors: Raji A, Winkler G
Presentation ID: P0586
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: A Raji
Title: Early Real-World Safety, Tolerability, and Efficacy of Cladribine Tablets: A Single Center Experience
Authors: Bain J, Jones A, Overholt S, Guenette M, Selchen D, Jiwon Oh
Presentation ID: P0319
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: J Bain
Title: Switching From Ocrelizumab to Cladribine: Real-world Data
Authors: O'Neill DTD, Sharma M, Gonzales B, Vandenheuvel M, Tse B, Hodgkinson SJ
Presentation ID: P0399
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: D O'Neill
Title: The Effect of Cladribine Upon Naive and Activated CD4+ T Regulatory Cells in MS Patients
Authors: Verma ND, Al-Atiyah R, O'Neill D, Sharma M, Tran CT, Hall BM, Hodgkinson SJ
Presentation ID: P0406
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Suzanne Hodgkinson
Rebif(R) (interferon beta-1a) Presentations
Title: A Systematic Review and Meta-analyses of Pregnancy and Fetal Outcomes in Women with Multiple Sclerosis. IMI2 ConcePTION
Authors: Lopez-Leon S, Geissbuehler Y, Sabido M, Turkson, M, Wahlich C, Morris J
Presentation ID: P0278
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Meritxell Sabido
Title: Post-approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections
Authors: Freedman M S, Guehring H, Murgasova Z, Jack D
Presentation ID: P0370
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Mark Freedman
Title: Effect of Neutralizing Antibodies on Pharmacodynamic Biomarkers of Subcutaneous Interferon β-1a in REFLEX and REFLEXION
Authors: Freedman MS, Holmberg KH, Fluck M, Hyvert H, Stinchi S, D'Urso V, Dangond F
Presentation ID: P0323
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Mark Freedman
Title: Baseline Serum Neurofilament Light Chain Levels Predict Conversion to McDonald 2005 MS Within 2 yrs of a First Clinical Demyelinating Event in REFLEX
Authors: Kuhle J, Leppert D, Comi G, De Stefano N, Kappos L, Freedman MS, Issard D, Roy S
Presentation ID: P0032
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Sanjeev Roy
Title: Effect of age on Effectiveness and Discontinuation of Subcutaneous Interferon beta-1a, and Healthcare Utilization, in Patients With Multiple Sclerosis
Authors: Sabido M, Allignol A Marhardt K, Vermersch P, Boutmy EF
Presentation ID: P0320
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Patrick Vermersch
Title: Comparing Infection-related Outcomes in Patients with Multiple Sclerosis and Matched Controls Using Administrative Claims Data
Authors: Bove R, Kozma C, Phillips AL, Harlow DE, Lobo C
Presentation ID: P0451
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Riley Bove
Title: Assessment of the Effectiveness of a Cognitive Behavioral Program for Fatigue (FACETS +) in 110 French Patients with Relapsing Remitting Multiple Sclerosis (RR MS): A randomized, controlled trial (RCT)
Authors: Hemelin F, Marie Claire G, Olivier H, Marie B, Frederic B
Presentation ID: P1095
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Fanny Hamelin
Title: Impact of Interferon-beta Exposure During Early Pregnancy on Relapse Rate
Authors: Tokic M, Thiel S, Litvin N, Ciplea A, Gold R, Hellwig K
Presentation ID: P1126
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: M Tokic
Evobrutinib Presentations
Title: Clinical Relapse Rates in Relapsing MS Patients Treated with the BTK Inhibitor Evobrutinib: Results of an Open-Label Extension to Phase II Study
Authors: Montalban X, Arnold D L, Weber MS, Staikov I, Piasecka-Stryczynska K, Martin E C, Mandel M, Ona V, Dangond F, Wolinsky JS
Presentation ID: P0197
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Fernando Dengond
Title: Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Relapsing Multiple Sclerosis During an Open-label Extension to a Phase II Study
Authors: Montalban, X Arnold D L, Weber M S, Staikov I, Piasecka-Stryczynska K, Martin E C, Mandel M, Ona V, Zima Y, Dengond F, Tomic D, Wolinsky JS
Presentation ID: P0235
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Fernando Dengond
Title: Effect Of Evobrutinib, a BTK Inhibitor, on Immune Cell and Immunoglobulin Levels in Relapsing MS: An Open-Label Extension to a Phase II Study
Authors: Montalban X, Shaw J, Dangond F, Martin EC, Grenningloh R, Ying Li, Weber MS
Presentation ID: P0070
Presentation Details:
- Session: ePoster
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Jamie Shaw
Title: Evobrutinib, a Highly Selective BTK Inhibitor, Prevents Antigen-activation of B Cells and Ameliorates B Cell-mediated Experimental Autoimmune Encephalomyelitis
Authors: Torke S, Pretzsch R, Hausler D, Grenningloh R, Boschert U, Bruck W, Weber MS
Presentation ID: P0334
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Sebastian Torke
Title: Expression of Bruton's Tyrosine Kinase in B Cell-rich Meningeal Infiltrates in two Models of Progressive MS
Authors: Kebir H, Ceja G, Miller MC, Li C, May MJ, Vite CH, Church ME, Grenningloh R, Boschert U, Alvarez JI
Presentation ID: P0962
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Kebir Hania
Title: T-bet+ B-cell Development in MS: Association with Bruton's Tyrosine Kinase Activity and Targeting by Evobrutinib
Authors: Rijvers L, Melief MJ, van Langelaar J, Wierenga-Wolf AF, Marieke van Ham S, Boschert U, Grenningloh R, Smolders J, van Luijn MM
Presentation ID: P0403
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT 11 September 2020
- Presenter: Liza Rijvers
Title: The Bruton's Tyrosine Kinase Inhibitor Evobrutinib Ameliorates Meningeal Inflammation in Experimental Autoimmune Encephalomyelitis
Authors: Kim S, Boschert U Grenningloh R, Bhargava P
Presentation ID: P0404
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Pavan Bhargava
Title: The Validity and Applicability of the PROMIS SF v2.1 - Physical Function (MS) 15a: A new PROMIS(R) Short Form for Assessing Physical Function in Relapsing and Progressive Multiple Sclerosis Types
Authors: Kamudoni P, Amtmann D, Johns J, Cook K, Salem R, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G, Wundes A, Henke C
Presentation ID: P1062
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Paul Kamudoni
Title: The Interpretation and Clinical Application of the PROMIS(R) SF v1.0 - Fatigue (MS) 8b: A PROMIS Short Form for Assessing Fatigue in Relapsing and Progressive Multiple Sclerosis
Authors: Kamudoni P, Johns J, Cook K, Salem R, Henke C, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G,Wundes A, Amtmann D
Presentation ID: P1061
Presentation Details:
- Session: ePoster
- Date: 11-13 September 2020
- Time: Available from 9am EDT on 11 September 2020
- Presenter: Paul Kamudoni
Source: Marck
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
<저작권자(c) 연합뉴스, 무단 전재-재배포 금지>
관련뉴스
